
MSD Sues German Health Insurance Savings Package in Karlsruhe Federal Court
MSD, the German subsidiary of the US pharmaceutical company Merck, has filed a constitutional complaint in Karlsruhe against central regulations of the Statutory Health Insurance Contribution Rate Stabilization Act. This was stated by the Chairman of MSD Germany, Kevin Peters, to the "Handelsblatt" (Friday edition).
The reform, passed in July, jeopardizes innovation and market access for new therapies in Germany. "Parts of this law are disproportionate. This is unacceptable and massively harmful," said Peters. The pharma manager stated that in his 35 years of career, he has never seen anything comparable. "The bridge is crumbling and risks breaking."
According to calculations by the Association of Pharmaceutical Manufacturers (Vfa), the projected savings for the pharmaceutical industry in 2028 amount to 4.8 billion euros. Peters said that one-fifth of this amount falls on MSD. This corresponds to almost one billion euros. "We would not file a constitutional complaint if we were not convinced," he said.
Peters explained that MSD does not want to withdraw from Germany. "The easier alternative would be a complete withdrawal - we reject that," he said. The corporation hopes that the complaint will bring more clarity and a cooperative attitude from the federal government in the coming months.











